Company Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai’s Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans.
Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Talat Imran |
Contact Details
Address: 2051 Ringwood Avenue San Jose, California 95131 United States | |
| Phone | 408 457 3700 |
| Website | ranitherapeutics.com |
Stock Details
| Ticker Symbol | RANI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 1856725 |
| CUSIP Number | 753018100 |
| ISIN Number | US7530181004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Talat Imran | Chief Executive Officer and Director |
| Mir A. Imran | Executive Chairman |
| Svai S. Sanford | Chief Financial Officer |
| Kate McKinley M.B.A. | Chief Business Officer |
| Alireza Javadi Ph.D. | Chief Technical Officer |
| Dr. Mir Hashim | Chief Scientific Officer |
| Bella Vazquez | Senior Vice President of People and Administrative Services |
| Jesper Hoeiland M.Sc. | Head of Strategy |
| Arvinder Dhalla | Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | SCHEDULE 13G | Filing |
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |